Key details
Phase
Early testing / Safety & dosing
Sponsor
Shanghai Hengrui Pharmaceutical Co., Ltd.
Enrollment target
~150 participants
Primary completion
May 2025
This trial's estimated completion date has passed — the record may not be fully up to date.
Age range
18 Years and older
Last updated January 2025